Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

NCT02689440 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

155

Enrollment

OTHER

Sponsor class

Conditions

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Interventions

DRUG: Dasatinib
OTHER: Laboratory Biomarker Analysis
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]